Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 29   

Articles published

ARNA 1.68 -0.10 (-5.62%)
price chart
Arena Pharmaceuticals Inc. (NASDAQ:ARNA) Fights for Share of Weight-loss Pill ...
Arena Pharmaceuticals Inc. (NASDAQ:ARNA, ARNA message board) is expected to launch its patented Belviq treatment early next year, but there are some doubts that by that time Vivus, Inc. (NASDAQ:VVUS) will have made its Qsymia something of a ...
Obesity Drugs Gain Attention on FDA Backing for Therapies
Third Rock Ventures is an early backer of Zafgen Inc., a biotechnology company in mid-stage trials of a therapy to treat obesity. The Food and Drug Administration cleared Belviq, from Arena Pharmaceuticals Inc. and Eisai Co., in June and Vivus Inc.'s ...
Not Another 'Rabbi for Obama'
At this moment, there are over 600 rabbis signed on as “Rabbis for Obama.” But Rabbi David Wolpe, who will be delivering a benediction Wednesday night at the Democratic National Convention, isn't one of them.
Murdock Trust: A Vancouver powerhouse of charitable giving
A community ice arena in Post Falls, Idaho, and a World Kite Museum in Washington's Long Beach. Mentoring money for K-12 science teachers ... Murdock has given away more than $650 million since it was created in 1975 by the will of high-tech titan ...
Time Out abandons its cover price
Jo Blake, head of print and radio investment at media buying firm Arena Media says Time Out is now charging rates of �5,000 to �5,500 a page, against previous comparable prices of about �2,000.
Are pet drugs like contact lenses?
The antitrust litigation did more to open the market than the Fairness to Contact Lens Consumers Act, which followed two years later, said Menderes “Mendo” Akdag, a former president and CEO of Lens Express Inc., a seller of replacement contact lenses.
FedEx Sees First Earnings Decline Since 2009 on Economy
Memphis-based FedEx operates the world's biggest cargo airline and is considered an economic bellwether because it moves goods ranging from financial documents to pharmaceuticals. Profit for the quarter that ended Aug. 31 will be $1.37 to $1.43 a share ...
Arena: DEA Schedule IV Will Make Belviq The Obesity Blockbuster Drug
Retail investors were right and Wall Street was wrong about the approval of Arena Pharmaceuticals' (NASDAQ:ARNA) lead drug candidate Belviq (Lorcaserin).
Ten Pharmaceutical Companies Unite to Accelerate Development of New Medicines
Ten Pharmaceutical Companies Unite to Accelerate Development of New Medicines ... Abbott, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson, Pfizer, Genentech a member of the Roche Group ...
FDA poised to tighten oversight of therapeutic pet foods
The U.S. Food and Drug Administration (FDA) is scrutinizing pet foods with labels claiming to treat or mitigate disease, suggesting that the sale of some brands call for a veterinary directive much like that of prescription medications.